|
|
Anacor has created a highly focused and productive research organization that has progressed
several internal compounds into the clinic since our founding in 2002. With additional compounds at various early
stages, preclinical and Phase I, Anacor has a growing pipeline, with an expanding clinical development portfolio
focused on developing topical applications of our compounds to treat fungal, bacterial and inflammatory diseases.
|
 
|